(Q33329060)

25 July 2017

title

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. (English)

1 reference

25 July 2017

1 reference

J P Stevenson

1

1 reference

25 July 2017

D DeMaria

2

1 reference

25 July 2017

J Sludden

3

1 reference

25 July 2017

S B Kaye

4

1 reference

25 July 2017

L Paz-Ares

5

1 reference

25 July 2017

L B Grochow

6

1 reference

25 July 2017

A McDonald

7

1 reference

25 July 2017

K Selinger

8

1 reference

25 July 2017

P Wissel

9

1 reference

25 July 2017

P J O'Dwyer

10

1 reference

25 July 2017

C Twelves

11

1 reference

25 July 2017

publication date

1 March 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

10

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

339-344

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

25 July 2017

1 reference

7 January 2021

DNA topoisomerase-targeting antitumor drugs can be studied in yeast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Determination of GI147211 in human blood by HPLC with fluorescence detection

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313011289

7 January 2021

Identifiers

DOI

10.1023/A:1008313011289

1 reference

25 July 2017

1 reference